Prescription Drug Supply Chain Pricing Transparency Act
This bill requires a federal study to investigate how hidden fees and payment structures among middlemen affect the cost of prescription drugs. It aims to uncover if current business practices encourage the use of more expensive medications over cheaper alternatives.
Key points
Investigation into how pharmacy benefit managers and wholesalers influence drug prices.
Examination of whether percentage-based fees lead to a preference for higher-priced drugs.
A report to Congress with recommendations to improve transparency and potentially lower costs for patients.
Analysis of conflicts of interest within the drug supply chain for Medicare and Medicaid programs.
Status:
Introduced
Civic Will
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens
(explained here).
Start recording it now.